VistaGen Therapeutics, Inc. Q3 FY2025 earnings call

Key Points

• Shawn Singh discussed progress on fasedienol: Palisade 3 and 4 Phase 3 trials for acute SAD treatment expected to yield top-line results in 2025; an exploratory Phase 2 repeat-dose study of fasedienol in SAD initiated. Progress on itruvone (planning Phase 2b) and PH80 (preparing IND submission).
• Cindy Anderson reported financials: Q3 2024 R&D expenses $11.3M vs $4.5M prior year; G&A expenses $4.0M vs $3.8M prior year; net loss $14.1M vs $6.4M prior year; cash, cash equivalents, and marketable securities $88.6M as of Dec 31, 2024.
• Positive results from exploratory Phase 2a trial of PH284 in cancer cachexia highlighted.

No detailed breakdown of product segments with absolute revenue and contribution %; focus is on clinical progress of pherine product candidates including fasedienol, itruvone, PH80, and PH284.

Guidance

• Confident that data from Palisade 3 and 4 will be released in 2025 as previously guided; no change in this guidance.

Q: Concerned about timing of Palisade 3 and 4 data and execution of studies.

A: Shawn Singh stated they are confident in seeing data from both Palisade 3 and 4 in 2025 with no change in guidance; Josh Prince mentioned enhanced execution with internal team and reduced reliance on CRO surveillance.

Q: Talk about competition in SAD and fasedienol's uniqueness.

A: Shawn Singh emphasized fasedienol's unique mechanism of nose-to-brain neurocircuitry, which is not seen in other approved drugs; this mechanism offers advantages like rapid onset and avoiding issues like drug-drug interactions.

Q: Color on AV-101 in neuropathic pain and rationale for clinician administration in Palisade 3 and 4.

A: Shawn Singh discussed AV-101's preclinical data in pain and Parkinson's-related dyskinesia; Josh Prince explained clinician administration in Palisade 3 and 4 was to reduce variability in the studies.

Q: Ongoing repeat-dose study for fasedienol and regulatory risk.

A: Josh Prince said the repeat-dose study is to align with FDA's request regarding potential second doses; no regulatory risk expected if Palisade 3 or 4 are positive as it would inform labeling.